Kenneth John Rodgers

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4132803/publications.pdf

Version: 2024-02-01

48 papers 1,684 citations

257450 24 h-index 276875 41 g-index

49 all docs 49 docs citations

49 times ranked 1908 citing authors

#	Article	IF	CITATIONS
1	Toxicity and bioaccumulation of two non-protein amino acids synthesised by cyanobacteria, \hat{l}^2 -N-Methylamino-L-alanine (BMAA) and 2,4-diaminobutyric acid (DAB), on a crop plant. Ecotoxicology and Environmental Safety, 2021, 208, 111515.	6.0	11
2	A Novel Method for Creating a Synthetic L-DOPA Proteome and In Vitro Evidence of Incorporation. Proteomes, 2021, 9, 24.	3.5	2
3	Cysteine biosynthesis contributes to \hat{l}^2 -methylamino-l-alanine tolerance in Escherichia coli. Research in Microbiology, 2021, 172, 103852.	2.1	1
4	\hat{l}^2 -Methylamino-L-alanine-induced protein aggregation in vitro and protection by L-serine. Amino Acids, 2021, 53, 1351-1359.	2.7	3
5	Acetonitrile adduct analysis of underivatised amino acids offers improved sensitivity for hydrophilic interaction liquid chromatography tandem mass-spectrometry. Journal of Chromatography A, 2021, 1655, 462530.	3.7	6
6	Misincorporation Proteomics Technologies: A Review. Proteomes, 2021, 9, 2.	3.5	4
7	Considerations for amino acid analysis by liquid chromatography-tandem mass spectrometry: A tutorial review. TrAC - Trends in Analytical Chemistry, 2020, 131, 116018.	11.4	41
8	Cell death and mitochondrial dysfunction induced by the dietary non-proteinogenic amino acid l-azetidine-2-carboxylic acid (Aze). Amino Acids, 2019, 51, 1221-1232.	2.7	10
9	L-DOPA causes mitochondrial dysfunction in vitro: A novel mechanism of L-DOPA toxicity uncovered. International Journal of Biochemistry and Cell Biology, 2019, 117, 105624.	2.8	10
10	Production of \hat{l}^2 -methylamino-L-alanine (BMAA) and Its Isomers by Freshwater Diatoms. Toxins, 2019, 11, 512.	3.4	33
11	Cytotoxicity and mitochondrial dysfunction caused by the dietary supplement l-norvaline. Toxicology in Vitro, 2019, 56, 163-171.	2.4	12
12	Prevalence of β-methylamino-L-alanine (BMAA) and its isomers in freshwater cyanobacteria isolated from eastern Australia. Ecotoxicology and Environmental Safety, 2019, 172, 72-81.	6.0	37
13	Investigation of the interaction of \hat{l}^2 -methylamino-l-alanine with eukaryotic and prokaryotic proteins. Amino Acids, 2018, 50, 397-407.	2.7	12
14	Detection of the suspected neurotoxin \hat{l}^2 -methylamino- l-alanine (BMAA) in cyanobacterial blooms from multiple water bodies in Eastern Australia. Harmful Algae, 2018, 74, 10-18.	4.8	34
15	Assessing the Combined Toxicity of BMAA and Its Isomers 2,4-DAB and AEG In Vitro Using Human Neuroblastoma Cells. Neurotoxicity Research, 2018, 33, 33-42.	2.7	22
16	Cyanobacterial Neurotoxins: Their Occurrence and Mechanisms of Toxicity. Neurotoxicity Research, 2018, 33, 168-177.	2.7	33
17	Oxidised protein metabolism: recent insights. Biological Chemistry, 2017, 398, 1165-1175.	2.5	11
18	Toxic Nonprotein Amino Acids. Toxinology, 2017, , 263-285.	0.2	2

#	Article	IF	Citations
19	LEARNER-GENERATED DIGITAL MEDIA (LGDM) FRAMEWORK., 2017,,.		1
20	The use of l-serine to prevent \hat{l}^2 -methylamino-l-alanine (BMAA)-induced proteotoxic stress in \hat{A} vitro. Toxicon, 2016, 109, 7-12.	1.6	29
21	Toxic Nonprotein Amino Acids. , 2015, , 1-20.		2
22	Using an in vitro model to study oxidised protein accumulation in ageing fibroblasts. Biochimica Et Biophysica Acta - General Subjects, 2015, 1850, 2177-2184.	2.4	8
23	The deleterious effects of non-protein amino acids from desert plants on human and animal health. Journal of Arid Environments, 2015, 112, 152-158.	2.4	15
24	Non-protein amino acids and neurodegeneration: The enemy within. Experimental Neurology, 2014, 253, 192-196.	4.1	52
25	The Non-Protein Amino Acid BMAA Is Misincorporated into Human Proteins in Place of I-Serine Causing Protein Misfolding and Aggregation. PLoS ONE, 2013, 8, e75376.	2.5	248
26	Aneurysm prevention: keep the cat out of the bag. Cardiovascular Research, 2012, 96, 350-351.	3.8	0
27	l-DOPA is incorporated into brain proteins of patients treated for Parkinson's disease, inducing toxicity in human neuroblastoma cells in vitro. Experimental Neurology, 2012, 238, 29-37.	4.1	41
28	Proteins containing oxidized amino acids induce apoptosis in human monocytes. Biochemical Journal, 2011, 435, 207-216.	3.7	26
29	Amino acid, peptide, and protein hydroperoxides and their decomposition products modify the activity of the 26S proteasome. Free Radical Biology and Medicine, 2011, 50, 389-399.	2.9	15
30	Inhibition of rupture of established atherosclerotic plaques by treatment with apolipoprotein A-I. Cardiovascular Research, 2011, 91, 37-44.	3.8	29
31	Heat shock proteins: keys to healthy ageing?. Redox Report, 2009, 14, 147-153.	4.5	18
32	Oxidized proteins: Mechanisms of removal and consequences of accumulation. IUBMB Life, 2009, 61, 522-527.	3.4	110
33	Evidence that DOPA-Derivatives are Generated After L-DOPA Incorporation into Proteins by Mammalian Cells. Journal of Adhesion, 2009, 85, 561-575.	3.0	1
34	Misincorporation of amino acid analogues into proteins by biosynthesis. International Journal of Biochemistry and Cell Biology, 2008, 40, 1452-1466.	2.8	104
35	The impact of specific oxidized amino acids on protein turnover in J774 cells. Biochemical Journal, 2008, 410, 131-140.	3.7	40
36	Evidence for L-dopa incorporation into cell proteins in patients treated with levodopa. Journal of Neurochemistry, 2006, 98, 1061-1067.	3.9	34

#	Article	IF	CITATIONS
37	Inhibition of cathepsins and related proteases by amino acid, peptide, and protein hydroperoxides. Free Radical Biology and Medicine, 2006, 40, 1539-1548.	2.9	55
38	Evidence for inactivation of cysteine proteases by reactive carbonyls via glycation of active site thiols. Biochemical Journal, 2006, 398, 197-206.	3.7	66
39	Destabilizing Role of Cathepsin S in Murine Atherosclerotic Plaques. Arteriosclerosis, Thrombosis, and Vascular Biology, 2006, 26, 851-856.	2.4	107
40	Translational incorporation of L-3,4-dihydroxyphenylalanine into proteins. FEBS Journal, 2005, 272, 3162-3171.	4.7	64
41	Biosynthesis and turnover of DOPA-containing proteins by human cells. Free Radical Biology and Medicine, 2004, 37, 1756-1764.	2.9	40
42	Assessment of proteasome activity in cell lysates and tissue homogenates using peptide substrates. International Journal of Biochemistry and Cell Biology, 2003, 35, 716-727.	2.8	89
43	Biosynthetic incorporation of oxidized amino acids into proteins and their cellular proteolysis. Free Radical Biology and Medicine, 2002, 32, 766-775.	2.9	67
44	Recent developments in the intracellular degradation of oxidized proteins 1,2 1Guest Editor: Earl Stadtman 2This article is part of a series of reviews on "Oxidatively Modified Proteins in Aging and Disease.―The full list of papers may be found on the homepage of the journal Free Radical Biology and Medicine, 2002, 33, 894-906.	2.9	77
45	Immunolocalisation of BPTI-like serine proteinase inhibitory proteins in mast cells, chondrocytes and intervertebral disc fibrochondrocytes of ovine and bovine connective tissues. An immunohistochemical and biochemical study. Histochemistry and Cell Biology, 2000, 114, 137-146.	1.7	6
46	Metabolism of protein-bound DOPA in mammals. International Journal of Biochemistry and Cell Biology, 2000, 32, 945-955.	2.8	47
47	Biotinylated trypsin and its application as a sensitive, versatile probe for the detection and characterisation of an ovine chondrocyte serine proteinase inhibitor using Western blotting. Electrophoresis, 1996, 17, 213-218.	2.4	9
48	Preparation and Use of Biotinylated Probes for the Detection and Characterisation of Serine Proteinase and Serine Proteinase Inhibitory Proteins., 1996,, 143-165.		0